Articles
April 22, 2019
BZ043, a novel long-acting amylin analog, reduces gastric emptying, food intake, glycemia and insulin requirement in streptozotocin-induced diabetic rats
Amylin analogs are important adjunctive drugs in the treatment of diabetes mellitus. However, a dual therapy with insulin involves inconvenient multiple injections. Here we describe a novel n-terminal PEGylated human amylin analog – BZ043 – and its potential to improve the control of glycemia using lower doses of insulin. The effect of BZ043 over the insulin-mediated control of fed-glycemia was investigated in rats with streptozotocin-induced diabetes treated with the basal analog glargine (GLAR). Fasted rats (3 h) received a single treatment of BZ043 (16, 64 or 128 nmol/kg), GLAR (1.5 IU or 6.0 IU) or BZ043 plus GLAR low dose (1.5 IU) in separate injections, and had free access to 5% glucose rich chow and water. BZ043 dose-proportionally prevented the meal-related increase of glycemia, and the co-treatment (64 or 128 nmol/kg) with GLAR restored normoglycemia without abrupt variations of glycemia. BZ043 showed a prolonged anti-hyperglycemic effect and, together with GLAR, promoted a long-lasting normoglycemia, in vivo. We conceive that combining BZ043 and GLAR in a fixed-ratio co-formulation might conveniently improve the control of diabetes mellitus.
Access the full paper co-authored by our patent specialist Caio França by clicking here.
Last related news
April 24, 2023
“Brazil: The patent combination conundrum” for LSIPR Magazine
Patents to new medicines usually protect the active ingredient (compound), provided that it is new and inventive. It is also a common … “Brazil: The patent combination conundrum” for LSIPR Magazine
February 16, 2023
Advertising Law | Year In Review | 2022
Kasznar Leonardos’ Marketing & Entertainment Law practice group is pleased to publish its first Advertising Law Year in Review newsletter highlighting the … Advertising Law | Year In Review | 2022
December 8, 2022
Digital influencers and advertising in the Metaverse and social media
When Facebook CEO and one of the planet’s wealthiest, Mark Zuckerberg, changed his company’s name to Meta in October 2021, he simultaneously … Digital influencers and advertising in the Metaverse and social media